ARTEMIS Precision Targeting
Precision Targeting
Eliminates prostate deformation for high accuracy of targeted biopsy
- Targeted MR/Ultrasound Biopsy
- 3D Semi Robotic Navigation for Prospective Targeting
- Patient Motion Compensation
- Custom Template Biopsy Plans
- 3D Needle Visualization & Pathology Recording
- Compatible with all U/S systems
- Easy Calibration
- Targeted mpUltrasound Bx
- Electromechanical Probe Stabilization
- Detailed Reporting including Previous Biopsy Cores
BENEFITS:
Clinical
Avoid freehand biopsy errors
Avoid freehand biopsy errors
Early detection of malignant tumors
Easy guidance to target anterior lesions
Active surveillance & focal therapy
Reduce repeat biopsy sessions
Operational
Quick set-up & intuitive workflow
No sensor-based needle supplies
No specialized room
PACS, cloud & network connectivity
Compatible with all MRI and U/S systems
Seamless radiology-urology integration
Financial
Reduce unnecessary biopsy costs
Reduce unnecessary supply costs
Cost benefits of early detection of PCa
Increased patient satisfaction & retention
Conventional U/S
Blind Poke & Hope Procedure
Detection Rate: 27-40%
False Negative Rate ~47%
38% Repeat Biopsy within 5 Years
Often Anterior Lesions Missed
Reduce unnecessary biopsy costs
mpMRI
Combine Anatomical & Functional Imaging Comparison of 3 Protocols in 83 Patients
| Protocol | Sensitivity | Specificity | Accuracy | AUC |
|---|---|---|---|---|
| T2W | 73% | 54% | 64% | 0.711 |
| T2W + DWI | 84% | 85% | 84% | 0.905 |
| T2W + DWI + DCE | 95% | 74% | 86% | 0.966 |
Multiparametric MRI has excellent sensitivity for detecting aggressive PCa Gleason score 7 or higher
Commitment to evidence-based medicine
| # Patients | 19 | 14 | 61 | 61 | 16 |
|---|---|---|---|---|---|
| # Any CaP | 6 | 6 | 29 | 34 | 15 |
| Gleason ≥ CaP | 3 | 1 | 9 | 14 | 7 |
94% of men with image grade 5 on MRI had PCa
Accurate targeting of lesions identified on mpMRI using ultrasound fusion biopsy in clinic
